When men are treated for a longer-duration antibiotic therapy for urinary tract infection (UTI), there is no decrease in early recurrence compared with those treated for a shorter duration, according to a study online in Archives of Internal Medicine.
FDA Issues Complete Response Letter for Pz-Cel to Treat Epidermolysis Bullosa
April 22nd 2024Prademagene zamikeracel is a cell therapy designed to incorporate the functional collagen-producing COL7A1 gene into a patient’s own skin cells. The FDA is asking for additional information on manufacturing practices.